Literature DB >> 2612543

Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers.

A Wahlländer1, G Paumgartner.   

Abstract

The effects of single oral doses of ketoconazole 400 mg and terbinafine 500 mg on the hepatic microsomal system have been investigated in 8 healthy male volunteers. Microsomal activity caffeine was assessed by following the metabolism of 3 mg/kg bodyweight i.v. administered 1 h after the drug. The inhibitory effect of terbinafine was more pronounced than that of ketoconazole: clearance was decreased from 1.34 ml.kg-1.min-1 in controls to 1.06 and 1.21 ml.kg-1.min-1, respectively, and the corresponding half-life was increased from 5.8 h in controls to 7.6 and 6.7 h, respectively. The apparent volume of distribution remained unchanged. The serum levels of the antimycotics were within the therapeutic range in each subject. Although all three substances are metabolised by microsomes, the kinetic parameters (Cmax, half-life, elimination constant) of the antimycotics were poorly if at all correlated with the elimination of caffeine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2612543     DOI: 10.1007/bf00679784

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Gyrase-inhibitors impair caffeine elimination in man.

Authors:  A H Staib; S Harder; S Mieke; C Beer; W Stille; P Shah
Journal:  Methods Find Exp Clin Pharmacol       Date:  1987-03

2.  Effect of ketoconazole and other imidazole fungicides on testosterone biosynthesis.

Authors:  T Schürmeyer; E Nieschlag
Journal:  Acta Endocrinol (Copenh)       Date:  1984-02

3.  The possible relationship between hepatic drug metabolism and ketoconazole enhancement of cyclosporine nephrotoxicity.

Authors:  M Gumbleton; J E Brown; G Hawksworth; P H Whiting
Journal:  Transplantation       Date:  1985-10       Impact factor: 4.939

4.  The interaction of representative members from two classes of antimycotics--the azoles and the allylamines--with cytochromes P-450 in steroidogenic tissues and liver.

Authors:  I Schuster
Journal:  Xenobiotica       Date:  1985-06       Impact factor: 1.908

5.  Effect of ketoconazole on hepatic oxidative drug metabolism.

Authors:  M W Brown; A L Maldonado; C G Meredith; K V Speeg
Journal:  Clin Pharmacol Ther       Date:  1985-03       Impact factor: 6.875

6.  Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes.

Authors:  M E Campbell; D M Grant; T Inaba; W Kalow
Journal:  Drug Metab Dispos       Date:  1987 Mar-Apr       Impact factor: 3.922

7.  Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase.

Authors:  G Petranyi; N S Ryder; A Stütz
Journal:  Science       Date:  1984-06-15       Impact factor: 47.728

Review 8.  Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use.

Authors:  J H Van Tyle
Journal:  Pharmacotherapy       Date:  1984 Nov-Dec       Impact factor: 4.705

9.  Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.

Authors:  J H Lin; A N Chremos; R Chiou; K C Yeh; R Williams
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

10.  Decreased systemic clearance of caffeine due to cimetidine.

Authors:  L J Broughton; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

View more
  10 in total

1.  [Use-risk consideration of anti-infective agents from the point of view of the licensing authority].

Authors:  W Christ; B Esch
Journal:  Infection       Date:  1991       Impact factor: 3.553

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 3.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

Review 4.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

Review 5.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 6.  Clinically significant pharmacokinetic interactions between dietary caffeine and medications.

Authors:  J A Carrillo; J Benitez
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

7.  Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers.

Authors:  E F Trépanier; A N Nafziger; G W Amsden
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

8.  A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs.

Authors:  Jasleen K Sodhi; Leslie Z Benet
Journal:  Clin Pharmacol Ther       Date:  2020-04-19       Impact factor: 6.875

Review 9.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Authors:  J A Balfour; D Faulds
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

10.  Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions.

Authors:  Jasleen K Sodhi; Caroline H Huang; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2021-02       Impact factor: 5.577

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.